Comparative Pharmacology
Head-to-head clinical analysis: BENICAR versus EDARBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR versus EDARBI.
BENICAR vs EDARBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.
Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.
EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 13–15 hours after multiple dosing, supporting once-daily dosing.
Approximately 20-22 hours in normal subjects; allows once-daily dosing. Half-life increases in moderate to severe hepatic impairment.
Olmesartan is excreted primarily in feces (approximately 50–65%) via biliary elimination, with about 35–50% eliminated renally in urine as unchanged drug.
Approximately 60% of dose is excreted in feces (primarily as unchanged drug) and 33% in urine (as metabolites, predominantly glucuronide conjugates).
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker